SPOMD Announces Name Change to SPO Global Inc. and

New Post Public Reply Private Reply Replies (0) Message Board
Compensated Post
shakerzzz
SPOMD >>Announces Name Change to SPO Global Inc. and Completes Reverse Stock Split

NEW YORK, October 7, 2013 /PRNewswire/ --
SPO Global Inc. (SPOM), formerly known as SPO Medical Inc., a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, announced today that its previously announced corporate name change and 1 for 20 reverse stock split became effective on October 4, 2013, at 11:59 p.m.
Due to the corporate name change and reverse stock split, SPO's common stock will trade under a new CUSIP number, 78468T107, and will temporarily trade under the symbol "SPOMD" for 20 trading days commencing October 7, 2013, after which time the symbol will revert to "SPOM". More information on the corporate name change and reverse stock split is available in the Company's information statement filed with the Securities and Exchange Commission on September 13, 2013.
The Company changed its corporate name to SPO Global Inc. to better reflect the nature of its products and current business focus.
With respect to the reverse split, every twenty shares of the Company's issued and outstanding common stock have been converted into one issued and outstanding share of common stock. The par value remains unchanged at $ 0.01 per share, as has the number of shares of common stock authorized, which remains at 100,000,000. The number of shares of the Company's issued and outstanding common stock has been reduced to approximately 5,000,000. Any fractional shares have been rounded up to the next whole share. In addition, the reverse stock split will effect a proportionate adjustment to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options and warrants to purchase or acquire shares of the Company's common stock.
As part of this restructuring, SPO Global will now apply its proprietary technology through several vertical marketing divisions - SPO Wellness, SPO Baby, SPO Security and via its licensee SPO Medical. The IP portfolio of 12 issued patents enables the Company to manufacture its products in addition to licensing its technologies to appropriate client corporations for commercialization and distribution. More details can be found on our web site at http://www.spoglobal.com.
About SPO Global
SPO Global is a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-enhancing information within four key markets: sports, wellness, homecare monitoring and security. Its patented technology uses information gathered from the reflectance of light on the human body, in a noninvasive manner, to monitor key vital signs. The company manufactures its products in addition to licensing its technologies to appropriate client corporations for commercialization and distribution. For more information, visit http://www.spoglobal.com.
Forward Looking Statements
This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, expectations regarding the successful expansion of our product base, profitability, market acceptance of our products and new product applications, timing of new product launches, product performance, size of prospective markets, marketing strategies, success of our restructured operations and plans, our ability to generate fees or raise capital to support our business operations and plan, the sufficiency and availability of working capital, changes in economic conditions generally and in more specifically, the introduction of competing products, changes in our operating strategy or development plans, patent protection for our products and technologies, changes in economic conditions generally and in more specifically, in the markets we operate, changes in technology, legislative or regulatory changes that affect us and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2012. We undertake no obligation to revise or update any forward-looking statement for any reason.
Contact regarding this release: SPO Global, investors@spoglobal.com, +1-866-991-7766
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 172

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
Xiaomi's Smart Auto Factory Draws Global Media Praise

Updated Category News Views 178

Xiaomi Impresses Global Media in Beijing Factory Tour In the ever-changing world of NEVs (New Energy Vehicles), a tour of Xiaomi's smart auto factory in Beijing has made waves among global media folks. These scribes got an up-close look at Xiaomi's magic mix of tech and style on November 6, part of a grand media gathering. What's Under the Hood? Marcos Costa de Oliveira,...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 228

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Niagara Networks Boosts TLS 1.3 Decryption to 90+ Gbps

Updated Category News Views 73

In a digital era where encryption is racing ahead like a runaway train, Niagara Networks has stepped up with some serious muscle enhancements to their ePacketron platform. They're not just playing catch-up with the latest TLS 1.3 decryption capabilities; they're leading the charge with a robust over 90 Gbps performance—no small feat in today's encrypted traffic...

Continue Reading
AWS Boosts Agilix's AI Education in Sierra Leone

Updated Category News Views 21

Agilix Labs' Landmark Leap with AWS Just when you think you've got the grip on global education dynamics, a new wave hits your shores, this time courtesy of Agilix Labs and AWS. Agilix Labs snagged a grant from Amazon Web Services, carving a path that blends AI with educational equity in Sierra Leone. Now, if that doesn’t prick up investor ears or yank a few...

Continue Reading
Segway Powersports Ventures into Baja 1000: Ambitions Run High

Updated Category News Views 124

They're gunning for glory in the sands of Baja, folks—Segway Powersports is about to rev up the excitement with its Baja 1000 debut. Never heard before in this legendary race's chronicles, Segway aims to shake up the game with their two brawny Super Villain UTVs. These aren't your run-of-the-pavement ride-ons; they're built for the rough stuff—and if there's a stage...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 119

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Ericsson Buybacks: Strategic Moves or Market Maneuver?

Updated Category News Views 10

Breaking Down Ericsson's Strategic Share Buybacks When a company like Ericsson starts pulling stocks off the shelves like they're on sale, it's time to take notice. Between November 2nd and 6th, Ericsson, that telecom giant we all know, went on a little shopping spree, snapping up 500,000 of its own Class B shares. Why should we care? Well, it's a part of their hefty SEK...

Continue Reading
Inside Kristallnacht: An XR Journey for a New World

Updated Category News Views 67

Bridging the Past with Powerful Tech: A Journey to Kristallnacht Let's cut to the chase: if there's a time in history that we all need to sear into our collective consciousness, it's Kristallnacht. Forget the mere notion of reading it from a textbook; now you can dive headfirst into the harrowing events of November 9, 1938, thanks to the cutting-edge initiative inside...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 481

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading

Top 5 Most Recently Viewed Articles

TC BioPharm's Continued Trading Highlights Market Confidence

Updated Category News Views 156

TC BioPharm Continues to Trade On Nasdaq TC BioPharm (Holdings) PLC, recognized by the ticker symbol TCBP, is actively trading on the Nasdaq Global Select Market. This clinical-stage biotechnology company is notably focused on developing allogeneic gamma-delta T cell therapies, primarily targeting cancer and various other medical conditions. Sustained Trading Activity The...

Continue Reading
Innovative AI Partnership Enhances Retail Security Solutions

Updated Category News Views 65

RaptorVision and Veesion Unite for Retail Excellence In a significant development for the retail industry, RaptorVision and Veesion have announced a global strategic partnership. This collaboration merges Veesion’s advanced concealment detection behavioral analytics with RaptorVision’s AI Event-Based Product Engagement and Integration Platform tailored for the retail...

Continue Reading
ADM's Q2 2025 Financial Performance: Insights and Trends

Updated Category News Views 152

ADM's Financial Overview for Q2 2025 ADM Aéroports de Montréal has released its financial results for the second quarter of 2025. This comprehensive report encompasses passenger traffic data, revenue figures, and insights into ongoing capital investment projects at YUL Montréal-Trudeau International Airport. Key Highlights of the Q2 Results The second quarter of 2025...

Continue Reading
Octopus AIM VCT Welcomes New Non-Executive Director

Updated Category News Views 184

Octopus AIM VCT Announces a Strategic Appointment Octopus AIM VCT plc is thrilled to share the exciting news of David Docherty joining the team as an independent Non-Executive Director. His official start will follow the upcoming Annual General Meeting. This strategic move reflects the company's commitment to enhance its governance and leadership. A Wealth of Experience...

Continue Reading
Enhancing Cybersecurity: New Designation for Risk Management Pros

Updated Category News Views 177

Introducing the Associate in Cyber Risk Management Designation In today's digital age, cyber risks have become one of the most pressing challenges for organizations globally. An alarming number of C-level executives—87% according to a recent survey—acknowledge that their companies are not fully prepared to face potential cyberattacks. Recognizing this critical issue,...

Continue Reading